McKesson Corporation (MCK)
NYSE: MCK · Real-Time Price · USD
779.78
-4.27 (-0.54%)
At close: Jun 15, 2026, 4:00 PM EDT
769.90
-9.88 (-1.27%)
After-hours: Jun 15, 2026, 7:47 PM EDT
McKesson Revenue
In the fiscal year ending March 31, 2026, McKesson had annual revenue of $403.43B with 12.36% growth. McKesson had revenue of $96.30B in the quarter ending March 31, 2026, with 6.02% growth.
Revenue (ttm)
$403.43B
Revenue Growth
+12.36%
P/S Ratio
0.23
Revenue / Employee
$9,382,093
Employees
43,000
Market Cap
91.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 403.43B | 44.38B | 12.36% |
| Mar 31, 2025 | 359.05B | 50.10B | 16.22% |
| Mar 31, 2024 | 308.95B | 32.24B | 11.65% |
| Mar 31, 2023 | 276.71B | 12.75B | 4.83% |
| Mar 31, 2022 | 263.97B | 25.74B | 10.80% |
| Mar 31, 2021 | 238.23B | 7.18B | 3.11% |
| Mar 31, 2020 | 231.05B | 16.73B | 7.81% |
| Mar 31, 2019 | 214.32B | 5.96B | 2.86% |
| Mar 31, 2018 | 208.36B | 9.82B | 4.95% |
| Mar 31, 2017 | 198.53B | 7.65B | 4.01% |
| Mar 31, 2016 | 190.88B | 11.84B | 6.61% |
| Mar 31, 2015 | 179.05B | 41.65B | 30.32% |
| Mar 31, 2014 | 137.39B | 15.20B | 12.44% |
| Mar 31, 2013 | 122.20B | -125.00M | -0.10% |
| Mar 31, 2012 | 122.32B | 10.24B | 9.13% |
| Mar 31, 2011 | 112.08B | 3.38B | 3.11% |
| Mar 31, 2010 | 108.70B | 2.07B | 1.94% |
| Mar 31, 2009 | 106.63B | 4.93B | 4.85% |
| Mar 31, 2008 | 101.70B | 8.73B | 9.39% |
| Mar 31, 2007 | 92.98B | 5.99B | 6.89% |
| Mar 31, 2006 | 86.98B | 7.89B | 9.97% |
| Mar 31, 2005 | 79.10B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cencora | 328.68B |
| Cardinal Health | 250.74B |
| Henry Schein | 13.38B |
| Accendra Health | 2.72B |
| 111, Inc. | 1.65B |
| Cosmos Health | 69.49M |
| Synergy CHC | 27.70M |
| Cellyan Biotechnology | 16.36M |
MCK News
- 3 days ago - McKesson Proxy statement: Proxy filing - Filings
- 3 days ago - McKesson Proxy statement: Proxy filing - Filings
- 5 days ago - McKesson price target lowered to $925 from $1,050 at Barclays - TheFly
- 13 days ago - McKesson closes investment with Apollo Funds for minority interest in MMS - TheFly
- 13 days ago - McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions - Business Wire
- 4 weeks ago - McKesson price target lowered to $945 from $975 at Citi - TheFly
- 4 weeks ago - McKesson Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - McKesson price target raised to $1,050 from $1,000 at UBS - TheFly